
%0 Journal Article
%T Association of metformin use with fracture risk in type 2 diabetes: a systematic review and meta-analysis of observational studies
%J Frontiers in endocrinology
%D 2022
%A Wang, Yining
%A Yu, Liming
%A Ye, Zhiqiang
%A Lin, Rui
%A Sun, Antonia RuJia
%A Liu, Lingna
%A Wei, Jinsong
%A Deng, Feifu
%A Zhong, Xiangxin
%A Cui, Liao
%A Li, Li
%A Liu, Yanzhi
%V 13
%N 
%P e1038603-e1038603
%X AIMS: Increasing evidence suggests that metformin can affect bone metabolism beyond its hypoglycemic effects in diabetic patients. However, the effects of metformin on fracture risk in type 2 diabetes mellitus (T2DM) patients remain unclear. A systematic review and meta-analysis were performed in this study to evaluate the association between metformin application and fracture risk in T2DM patients based on previous studies published until June 2021. <br><br>METHODS: A systematic search was performed to collect publications on metformin application in T2DM patients based on PubMed, Embase, Cochran, and Web of Science databases. Meta-analysis was performed by using a random-effects model to estimate the summary relative risks (RRs) with 95% confidence intervals (CIs). Subgroup analyses based on cohort/case-control and ethnicity and sensitivity analyses were also performed. <br><br>RESULTS: Eleven studies were included in the meta-analysis. <br><br>RESULTS demonstrated metformin use was not significantly associated with a decreased risk of fracture (RR, 0.91; 95% CI, 0.81-1.02; I(2 =) 96.8%). Moreover, metformin use also demonstrated similar results in subgroup analyses of seven cohort studies and four case-control studies, respectively (RR, 0.90; 95% CI, 0.76-1.07; I(2 =) 98.0%; RR, 0.96; 96% CI, 0.89-1.03; I(2 =) 53.7%). Sensitivity analysis revealed that there was no publication bias. <br><br>CONCLUSION: There was no significant correlation between fracture risk and metformin application in T2DM patients. Due to a limited number of existing studies, further research is needed to make a definite conclusion for clinical consensus.<p /> <p>Language: en</p>
%G en
%I Frontiers Research Foundation
%@ 1664-2392
%U http://dx.doi.org/10.3389/fendo.2022.1038603